Monopar Therapeutics Inc.
MNPR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.14 | 3.23 | 0.40 | -0.01 |
| FCF Yield | -0.36% | -0.43% | -2.25% | -0.79% |
| EV / EBITDA | -132.14 | -85.99 | -65.73 | -18.85 |
| Quality | ||||
| ROIC | -2.89% | -6.19% | -6.01% | -20.12% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.61 | 0.44 | 2.16 | 0.18 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -94.04% | 80.98% | -183.39% | -86.16% |
| Safety | ||||
| Net Debt / EBITDA | 37.11 | 16.07 | 12.33 | 4.19 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |